Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures

Gaetani, Lorenzo; Schoonheim, Menno M.

doi:10.1177/13524585221122916

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48 The elevated concentration of Nfl is commonly observed in patients with pronounced cognitive dysfunction. 49 Cognitive assessment Diagnostics of cognitive impairment is also relevant to patients with MS as it is detected in 30%-60% of cases.…”

Section: Evoked Potential Studiesmentioning

confidence: 99%

“…Nfl is a marker of neuronal injury in many neurodegenerative pathologies 48. The elevated concentration of Nfl is commonly observed in patients with pronounced cognitive dysfunction 49…”

Section: Introductionmentioning

confidence: 99%

“… 48 The elevated concentration of Nfl is commonly observed in patients with pronounced cognitive dysfunction. 49 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis

Statsenko,

Smetanina,

Arora

et al. 2023

BMJ Open

View full text Add to dashboard Cite

BackgroundThe number of patients diagnosed with multiple sclerosis (MS) has increased significantly over the last decade. The challenge is to identify the transition from relapsing-remitting to secondary progressive MS. Since available methods to examine patients with MS are limited, both the diagnostics and prognostication of disease progression would benefit from the multimodal approach. The latter combines the evidence obtained from disparate radiologic modalities, neurophysiological evaluation, cognitive assessment and molecular diagnostics. In this systematic review we will analyse the advantages of multimodal studies in predicting the risk of conversion to secondary progressive MS.Methods and analysisWe will use peer-reviewed publications available in Web of Science, Medline/PubMed, Scopus, Embase and CINAHL databases. In vivo studies reporting the predictive value of diagnostic methods will be considered. Selected publications will be processed through Covidence software for automatic deduplication and blind screening. Two reviewers will use a predefined template to extract the data from eligible studies. We will analyse the performance metrics (1) for the classification models reflecting the risk of secondary progression: sensitivity, specificity, accuracy, area under the receiver operating characteristic curve, positive and negative predictive values; (2) for the regression models forecasting disability scores: the ratio of mean absolute error to the range of values. Then, we will create ranking charts representing performance of the algorithms for calculating disability level and MS progression. Finally, we will compare the predictive power of radiological and radiomical correlates of clinical disability and cognitive impairment in patients with MS.Ethics and disseminationThe study does not require ethical approval because we will analyse publicly available literature. The project results will be published in a peer-review journal and presented at scientific conferences.PROSPERO registration numberCRD42022354179.

show abstract

Section: Evoked Potential Studiesmentioning

confidence: 99%

“…Nfl is a marker of neuronal injury in many neurodegenerative pathologies 48. The elevated concentration of Nfl is commonly observed in patients with pronounced cognitive dysfunction 49…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis

Statsenko,

Smetanina,

Arora

et al. 2023

BMJ Open

View full text Add to dashboard Cite

show abstract

Rituximab in secondary progressive multiple sclerosis: a meta‐analysis

Intarakhao,

Laipasu,

Jitprapaikulsan

et al. 2024

Ann Clin Transl Neurol

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy of rituximab (RTX) in stabilizing disability progression in secondary progressive multiple sclerosis (SPMS).MethodsA systematic review was conducted, encompassing studies from inception to April 2023, utilizing the MEDLINE and EMBASE databases. Inclusion criteria comprised studies with a minimum of 3 SPMS patients receiving intravenous RTX in at least one infusion, with a follow‐up duration of at least 6 months. Primary outcome measures included changes in Expanded Disability Status Scale (EDSS) scores. Mean differences in pre‐ and post‐RTX EDSS scores were analyzed using a random‐effects model. Meta‐regression examined age at RTX initiation, pre‐RTX EDSS scores, disease duration, and outcome reported time as variables. Secondary outcomes assessed changes in the annualized relapse rate (ARR).ResultsThirteen studies, involving 604 SPMS patients, met the inclusion criteria. Following a mean follow‐up of 2 years, the mean difference in EDSS scores (ΔEDSS = EDSSpre‐RTX − EDSSpost‐RTX) was −0.21 (95% CI −0.51 to 0.08, p = 0.16), indicating no significant variation. Multivariable meta‐regression identified significant associations between EDSS score mean difference and pre‐RTX EDSS scores, disease duration at RTX initiation, and outcome reported time. However, age at RTX initiation showed no significant association. Pre‐ and post‐RTX ARR data were available for 245 out of 604 SPMS patients across seven studies, revealing a mean difference in ARR (ΔARR = ARRpre‐RTX − ARRpost‐RTX) of 0.74 (95% CI 0.19–1.29, p = 0.008).InterpretationRTX demonstrates efficacy in reducing relapse frequency and exhibits potential in stabilizing disability progression over a 2‐year follow‐up, particularly among individuals with shorter disease duration.

show abstract

Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures

Cited by 2 publications

References 11 publications

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis

Rituximab in secondary progressive multiple sclerosis: a meta‐analysis

Contact Info

Product

Resources

About